{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:28:58Z","timestamp":1770906538679,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,6]]},"DOI":"10.7759\/cureus.59744","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T17:19:41Z","timestamp":1715015981000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Challenges of Haplo-Identical Hematopoietic Stem Cell Transplant in a Developing Country: A Single Center Experience"],"prefix":"10.7759","author":[{"given":"Ammad","family":"Akram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehwish","family":"Gilani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qamar un Nisa","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheel","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehreen Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Memoona","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haider","family":"Nisar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2021.12.399","article-title":"Hematopoietic stem cell gene editing and expansion: state-of-the-art technologies and recent applications","volume":"107","author":"Haltalli ML","year":"2022","unstructured":"Haltalli ML, Wilkinson AC, Rodriguez-Fraticelli A, Porteus M. Hematopoietic stem cell gene editing and expansion: state-of-the-art technologies and recent applications. Exp Hematol. 2022, 107:9-13. 10.1016\/j.exphem.2021.12.399","journal-title":"Exp Hematol"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125232","article-title":"One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation","volume":"134","author":"Niederwieser D","year":"2019","unstructured":"Niederwieser D, Baldomero H, Atsuta Y, et al.. One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the Worldwide Network for Blood and Marrow Transplantation. Blood. 2019, 134:2035.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1005042","article-title":"Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: a systematic review and meta-analysis","volume":"12","author":"Mushtaq MU","year":"2022","unstructured":"Mushtaq MU, Shahzad M, Tariq E, et al.. Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: a systematic review and meta-analysis. Front Oncol. 2022, 12:1005042. 10.3389\/fonc.2022.1005042","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg JR","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, et al.. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021, 56:1651-64. 10.1038\/s41409-021-01227-8","journal-title":"Bone Marrow Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0382-3","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study","volume":"54","author":"Yang J","year":"2019","unstructured":"Yang J, Jiang J, Cai Y, et al.. Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant. 2019, 54:1049-57. 10.1038\/s41409-018-0382-3","journal-title":"Bone Marrow Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101035","article-title":"Haploidentical transplants with a G-CSF\/ATG-based protocol: Experience from China","volume":"62","author":"Xu ZL","year":"2023","unstructured":"Xu ZL, Huang XJ. Haploidentical transplants with a G-CSF\/ATG-based protocol: Experience from China. Blood Rev. 2023, 62:101035. 10.1016\/j.blre.2022.101035","journal-title":"Blood Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2019.03.005","article-title":"Immune reconstitution after T-cell replete HLA-haploidentical transplantation","volume":"56","author":"McCurdy SR","year":"2019","unstructured":"McCurdy SR, Luznik L. Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Semin Hematol. 2019, 56:221-6. 10.1053\/j.seminhematol.2019.03.005","journal-title":"Semin Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_391_18","article-title":"Access to hematopoietic stem-cell transplantation in India","volume":"65","author":"Kulkarni U","year":"2019","unstructured":"Kulkarni U, George B. Access to hematopoietic stem-cell transplantation in India. J Postgrad Med. 2019, 65:1-4. 10.4103\/jpgm.JPGM_391_18","journal-title":"J Postgrad Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00771-w","article-title":"Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial","volume":"13","author":"Zu Y","year":"2023","unstructured":"Zu Y, Gui R, Li Z, et al.. Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial. Blood Cancer J. 2023, 13:10. 10.1038\/s41408-022-00771-w","journal-title":"Blood Cancer J"},{"key":"ref10","article-title":"Haplo-identical transplants using post transplant cyclophosphamide (PTCy) are associated with good outcomes if transplanted with early disease-a single centre analysis from India","volume":"29","author":"George B","year":"2018","unstructured":"George B, Abraham A, Korula A, et al.. Haplo-identical transplants using post transplant cyclophosphamide (PTCy) are associated with good outcomes if transplanted with early disease-a single centre analysis from India. Blood. 2018, 29:4652.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.028","article-title":"Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"25","author":"Arcuri LJ","year":"2019","unstructured":"Arcuri LJ, Aguiar MT, Ribeiro AA, Pacheco AG. Haploidentical transplantation with post-transplant cyclophosphamide versus unrelated donor hematopoietic stem cell transplantation: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019, 25:2422-30. 10.1016\/j.bbmt.2019.07.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs EJ","year":"2022","unstructured":"Fuchs EJ, McCurdy SR, Solomon SR, et al.. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022, 139:1452-68. 10.1182\/blood.2021013443","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.31547\/bct-2020-013","article-title":"The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region","volume":"4","author":"Iida M","year":"2021","unstructured":"Iida M, Dodds A, Akter M, et al.. The 2016 APBMT Activity Survey Report: Trends in haploidentical and cord blood transplantation in the Asia-Pacific region. Blood Cell Ther. 2021, 4:20-8. 10.31547\/bct-2020-013","journal-title":"Blood Cell Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern AE","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, Jones RJ. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021, 5:1360-8. 10.1182\/bloodadvances.2020003922","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25826","article-title":"CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)","volume":"95","author":"Maffini E","year":"2020","unstructured":"Maffini E, Labopin M, Blaise D, et al.. CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2020, 95:892-9. 10.1002\/ajh.25826","journal-title":"Am J Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.12.006","article-title":"Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is safe and feasible","volume":"27","author":"Colunga-Pedraza PR","year":"2021","unstructured":"Colunga-Pedraza PR, G\u00f3mez-De Le\u00f3n A, Rodr\u00edguez-Roque CS, et al.. Outpatient haploidentical stem cell transplantation using post-transplant cyclophosphamide is safe and feasible. Transplant Cell Ther. 2021, 27:259.e1-6. 10.1016\/j.jtct.2020.12.006","journal-title":"Transplant Cell Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25993","article-title":"Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study","volume":"96","author":"Cho BS","year":"2021","unstructured":"Cho BS, Min GJ, Park S, et al.. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study. Am J Hematol. 2021, 96:98-109. 10.1002\/ajh.25993","journal-title":"Am J Hematol"},{"key":"ref18","article-title":"Sero-prevalence of human cytomegalovirus among blood donors in Lahore, Pakistan","volume":"25","author":"Rizvi CB","year":"2015","unstructured":"Rizvi CB, Raza A, Siddiqui MF. Sero-prevalence of human cytomegalovirus among blood donors in Lahore, Pakistan. Adv in Life Sci. 2015, 25:171-5.","journal-title":"Adv in Life Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00600-z","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India","volume":"39","author":"Uppuluri R","year":"2019","unstructured":"Uppuluri R, Sivasankaran M, Patel S, et al.. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India. J Clin Immunol. 2019, 39:182-7. 10.1007\/s10875-019-00600-z","journal-title":"J Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13626","article-title":"Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Kerbauy MN","year":"2021","unstructured":"Kerbauy MN, Ribeiro AA, Arcuri LJ, et al.. Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2021, 23:e13626. 10.1111\/tid.13626","journal-title":"Transpl Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.10.009","article-title":"Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis","volume":"27","author":"Lin A","year":"2021","unstructured":"Lin A, Flynn J, DeRespiris L, et al.. Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. Transplant Cell Ther. 2021, 27:85.e1-6. 10.1016\/j.bbmt.2020.10.009","journal-title":"Transplant Cell Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.011","article-title":"Hematopoietic stem cell transplantation in Nepal: international partnership, implementation steps, and clinical outcomes","volume":"28","author":"Poudyal BS","year":"2022","unstructured":"Poudyal BS, Tuladhar S, Neupane S, et al.. Hematopoietic stem cell transplantation in Nepal: international partnership, implementation steps, and clinical outcomes. Transplant Cell Ther. 2022, 28:268-75. 10.1016\/j.jtct.2022.02.011","journal-title":"Transplant Cell Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.020","article-title":"Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications-a single center experience from India","volume":"28","author":"George B","year":"2022","unstructured":"George B, Kulkarni U, Lionel S, et al.. Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications-a single center experience from India. Transplant Cell Ther. 2022, 28:45.e1-8. 10.1016\/j.jtct.2021.09.020","journal-title":"Transplant Cell Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.921293","article-title":"Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia","volume":"13","author":"Barkhordar M","year":"2022","unstructured":"Barkhordar M, Kasaeian A, Janbabai G, et al.. Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Front Immunol. 2022, 13:921293. 10.3389\/fimmu.2022.921293","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/207086-real-world-challenges-of-haplo-identical-hematopoietic-stem-cell-transplant-in-a-developing-country-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T17:20:06Z","timestamp":1715016006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/207086-real-world-challenges-of-haplo-identical-hematopoietic-stem-cell-transplant-in-a-developing-country-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.59744","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}